Longevity & Aging
Can gene "reprogramming" reverse age-related vision loss?
The claim, precisely: partial reprogramming (OSK) mitigates age-related vision loss
Strong support Longevity & Aging 🐭 Non-human evidence
RefutedContestedStrong support
consensus score 0.91
Yes, it restored sight after injury and ageing, but only shown in mice so far, with no human data.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
10 support 0 contradict 0 tested null 2 mixed · 12 sources, 8 independent groups
What the evidence shows
OSK (Myc omitted to limit cancer risk) regenerates optic-nerve axons and restores vision after injury/glaucoma/aging in MICE via TET-dependent demethylation (Lu-Sinclair 2020). Striking but species- and tissue-limited; no human data.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Paine 2023 · Front Aging | animal | supports | moderate | Independent lab: initiation-phase in vivo reprogramming ameliorated DNA damage in ERCC1 progeroid mice, supporting OSK partial-reprogramming rejuvenation mechanism (non-ocular). |
| Yang JH 2023 · Aging (Albany) | in-vitro | supports | moderate | Chemically-induced OSK-based reprogramming reversed cellular-aging markers (DNA methylation, transcriptome) without loss of identity - mechanistic basis for the OSK vision work (same lab). |
| Zhang K 2024 · Invest Ophthalmol Vis Sci | animal | supports | moderate | Reprogramming-based induced retinal ganglion cell model: Shootin1 regulates RGC neurite/axon development, supporting reprogramming as a route to regenerate vision-relevant RGCs. |
| Paine PT 2024 · Aging Cell | in-vitro | mixed | moderate | Review of partial reprogramming: real rejuvenation signal across models but unresolved tumour/safety risk and no human efficacy data - tempers the vision claim. |
| Yang 2023 · Cell | animal | supports | low | [FT-verified] ICE/Cell2023 same Sinclair lab reaffirms; reinforces not independent. ANIMAL-ONLY ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
| Jo BK 2025 · Aging Cell | in-vitro | mixed | low | Review of in vivo reprogramming: promising organ-specific dedifferentiation but persistent safety/clinical-applicability concerns; vision restoration remains preclinical. |
| Lu 2020 · Nature | animal | supports | moderate | [FT-verified] Lu-Sinclair Nature2020 MOUSE RGC OSK restores vision via TET demethylation. ANIMAL-ONLY species caveat |
| Zhang K 2026 · Stem Cell Reports | in-vitro | supports | moderate | Mettl3/m6A promotes reprogramming and axonogenesis of induced retinal ganglion cells - mechanistic support for reprogramming-driven RGC regeneration. |
| Nakatsukasa 2025 · Regen Ther | mechanism | supports | low | [FT-verified] Yamada review in-vivo partial reprogramming citing restored vision. ANIMAL/MECHANISM-ONLY |
| Nunez-Quintela 2026 · Trends Mol Med | mechanism | supports | moderate | [FT-verified] Collado review partial reprogramming rejuvenates tissue/regen capacity. ANIMAL/MECHANISM-ONLY |
| Alle Q 2022 · Aging Cell | animal | supports | moderate | Independent lab: a single short in vivo OSKM reprogramming pulse improved tissue function and healthspan in mice, supporting OSK rejuvenation generality (non-ocular). |
| Schoenfeldt L 2025 · EMBO Mol Med | animal | supports | moderate | Independent lab: chemical (OSK-mimetic) reprogramming ameliorated aging hallmarks and extended lifespan in mice - corroborates reprogramming-rejuvenation mechanism (non-ocular). |
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.